Orexo’s Edluar receives FDA approval for the treatment of insomnia

STOCKHOLM A Swedish pharmaceutical company announced Monday that it has received approval from the Food and Drug Administration for its short-term treatment for insomnia.

Edluar (formerly Sublinox) will be available in 5 mg and 10 mg sublingual tablets.

Orexo's U.S. partner, Meda, acquired the exclusive worldwide commercialization license for Edluar is set to market the drug during the second half of this year. Orexo will receive royalties on Meda’s sales of Edluar.

Orexo is a pharmaceutical company focused on developing drugs for the treatment of pain and inflammation.